ReviewClinical interventions in aging2007
Immunosupportive therapies in aging.
Review in Clinical interventions in aging, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 70 citations in OpenAlex.
- Natural killer cell-based senotherapy: a promising strategy for healthy aging.Frontiers in immunology · 2025Review
- Late-onset psoriatic arthritis: data from a nationwide cross-sectional study.Therapeutic advances in musculoskeletal disease · 2025Article
- Adoptive NK cell therapy: a potential revolutionary approach in longevity therapeutics.Immunity & ageing : I & A · 2024Review
- Aging and chronic inflammation: highlights from a multidisciplinary workshop.Immunity & ageing : I & A · 2023Review
- Immunomodulation in age-related disorders and nanotechnology interventions.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Article
- Cytomegalovirus Serostatus and Functional Impairment in Liver Transplant Recipients in the Current Era.Viruses · 2021Article
- Evaluating Immune Dysregulation in Patients With COVID-19 Requires a More Accurate Definition of the CD45RA+ T-cell Phenotype.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased α5β1 integrin expression.Journal of leukocyte biology · 2017Article
- Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients.Journal for immunotherapy of cancer · 2015Article
- Influence of oral supplementation with sesamin on longevity of Caenorhabditis elegans and the host defense.European journal of nutrition · 2014Article
- Evaluation of a Unani polyherbal formulation (Tiryaqe wabai) as an immunostimulator in elderly persons.Ancient science of life · 2013Article
- Altered molecular repertoire of immune system by renal dysfunction in the elderly: is prediction and targeted prevention in the horizon?The EPMA journal · 2013Article
- Vaccination in the elderly.Microbial biotechnology · 2012Review
- The safety of systemic treatments that can be used for geriatric psoriasis patients: a review.Dermatology research and practice · 2012Article
- Cancer surgery in the elderly.TheScientificWorldJournal · 2012Review
- A molecular mechanism for TNF-α-mediated downregulation of B cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Aging and immune function: molecular mechanisms to interventions.Antioxidants & redox signaling · 2011Review
- Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways.Current opinion in pharmacology · 2010Review
- Immunity, ageing and cancer.Immunity & ageing : I & A · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary role of the immune system is to protect the organism against pathogens, but age-associated alterations to immunity increase the susceptibility of the elderly to infectious disease. The exact nature of these changes is still controversial, but the use of screening procedures, such as the SENIEUR protocol to exclude underlying illness, helped to better characterize the changes actually related to physiological aging rather than pathology. It is generally agreed that the most marked changes occur in the cellular immune response reflecting profound alterations in T cells. Much of this is due to thymic involution as well as changes in the proportions of T cell subpopulations resulting from antigen exposure, and altered T cell activation pathways. However, a body of data indicates that innate immune responses, including the critical bridge between innate and adaptive immunity, and antigen presenting capacity are not completely resistant to senescence processes. The consequences of all these alterations are an increased incidence of infections, as well as possibly cancers, autoimmune disorders, and chronic inflammatory diseases. The leading question is what, if anything, can we do to prevent these deleterious changes without dangerously dysregulating the precarious balance of productive immunity versus immunopathology? There are many potential new therapeutic means now available to modulate immunosenescence and many others are expected to be available shortly. One main problem in applying these experimental therapies is ethical: there is a common feeling that as ageing is not a disease; the elderly are not sick and therefore do not require adventurous therapies with unpredictable side-effects in mostly frail individuals. Animal models are not helpful in this context. In this chapter we will first briefly review what we think we know about human immunosenescence and its consequences for the health status of elderly individuals. We will then discuss possible interventions that might one day become applicable in an appropriate ethical environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.